title: Peritoneal fibrosis leading to small bowel obstruction two years after first-line intraperitoneal chemotherapy for optimally debulked ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynaecology, Royal Hobart Hospital, Hobart, Tasmania, Australia. warren_chan@optusnet.com.au
authors.forename: Warren S W
authors.initials: WS
authors.lastname: Chan
authors.forename: Robert
authors.initials: R
authors.lastname: Bohmer
authors.forename: Robert
authors.initials: R
authors.lastname: McIntosh
authors.forename: Penelope
authors.initials: P
authors.lastname: Blomfield
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood; D002945:Cisplatin / Q000627:therapeutic use; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology* / Q000601:surgery; D007421:Intestine, Small / Q000187:drug effects / Q000503:physiopathology / Q000601:surgery; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017239:Paclitaxel / Q000627:therapeutic use; D056627:Peritoneal Fibrosis / Q000150:complications* / Q000601:surgery; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D003841:Deoxycytidine; D004317:Doxorubicin; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine